A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal ...

ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE EXPANSION OF WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALISE DAPAGLIFLOZIN IN JAPAN AstraZeneca and Bristol-Myers Squibb today announced ...

AstraZeneca Plc's (NASDAQ: AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 study evaluating dapagliflozin in adult patients with type 2 diabetes who were inadequately controlled on combination ...

AstraZeneca then added a second primary end point to its cardiovascular outcomes trial, DECLARE-TIMI 58, and results released in November 2018 showed that dapagliflozin significantly reduced the ...

The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.

AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without ...

Results from the anticipated DELIVER trial, presented at the European Society of Cardiology Congress, also showed participants assigned dapagliflozin (Farxiga, AstraZeneca), an SGLT2 inhibitor ...

In hospitalized patients with COVID-19, the SGLT2 inhibitor dapagliflozin was well tolerated regardless of kidney function, but did not significantly lower patients’ risk of organ failure ...

AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared ...

astrazeneca | dapagliflozin | heart failure. Related posts. Levicept presents new LEVI-04 data at EULAR. Jun 12, 2025. Migraine takes the spotlight at European Parliament. Jun 12, 2025. Bimekizumab ...